Jenscare Scientific’s LuX-Valve Fails to Gain Approval from China’s CDME
Ningbo-based structural heart disease device manufacturer Jenscare Scientific Co., Ltd (HKG: 9877) has announced that...
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi...
Sichuan Kelun Pharmaceutical Reports 12.69% YOY Revenue Growth in 2023 Financial Results
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a leading pharmaceutical company in China, has announced...
China Unveils 16-Measure Policy to Support Overseas Investment in Domestic Tech Firms
A coalition of 10 Chinese government bureaus, including the Ministry of Commerce, Ministry of Foreign...
Sanofi’s Rilzabrutinib Meets Primary Endpoint in Phase III ITP Trial
French pharmaceutical company Sanofi (NASDAQ: SNY) has announced that its Phase III trial for rilzabrutinib,...
China’s CSRC Unveils 16 Measures to Boost Capital Market and Tech Enterprises
The China Securities Regulatory Commission (CSRC) has introduced a comprehensive set of 16 measures aimed...
Novartis Reports 11% YOY Sales Growth in Q1 2024, Led by Entresto and Cosentyx
Swiss pharmaceutical giant Novartis (NYSE: NVS) has reported an 11% year-on-year (YOY) increase in constant...
Lepu Medical Technology Reports 2023 Revenues of RMB 7.98 Billion, Marking a 24.78% YOY Decrease
China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has released...
European Commission Approves Pfizer’s Antibiotic Emblaveo for Multiple Indications
The European Commission (EC) has granted approval for Pfizer’s (NYSE: PFE) antibiotic Emblaveo (aztreonam +...
BeiGene’s Tislelizumab Secures EC Approval for Three NSCLC Indications
BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the European Committee (EC) has...
Shanghai Henlius Biotech Achieves First Patient Dosing in Phase I Trial for Fibrosis Treatment HLX6018
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced the...
China’s Insulin Volume-Based Procurement Tender Results Renewed with 17% Higher Contracted Value
The renewal of winning bids from the insulin volume-based procurement (VBP) tender, initially held in...
China Medical System Holdings’ Desidustat NDA Accepted for Review by China’s NMPA
China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...
Akeso Biopharma Submits sNDA for Cadonilimab in Cervical Cancer to China’s CDE
China-based Akeso Biopharma (HKG: 9926) has announced the submission of a supplementary New Drug Application...
Huadong Medicine’s HDM1005 Receives US FDA Clinical Trial Approval for Weight Management
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial...
Sandoz’s Partner Samsung Bioepis Scores EC Approval for Stelara Biosimilar Pyzchiva
Switzerland-headquartered Sandoz (SWX: SDZ) has announced that the European Commission (EC) has granted approval for...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Go-Ahead for Camrelizumab Combination Therapy Study in Pancreatic Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has...
CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial...
CANbridge Pharmaceuticals’ CAN008 Fails to Meet Phase II Endpoints in Glioblastoma Multiforme
CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept)...